Patent · US Active

Crystalline form I of tyrosine kinase inhibitor dimaleate and preparation methods thereof

US9309226B2 · kind B2 · utility

2Cited by

0References

14Claims

0Family size

Assignee

JIANGSU HENGRUI MEDICINE CO., LTD. · CN

Inventors

Piaoyang Sun · Lianyungang, CN
Guaili Wu · 安丰镇, CN
Bo Yuan · Lo Wu, CN
Yongjiang Chen · 安丰镇, CN

Key dates

Filing date	Jun 4, 2013
Grant date	Apr 12, 2016
Priority date	—
Expiry date	Jun 4, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

Provided are crystalline Form I of (R,E)-N-(4-(3-chloro-4-(pyridin-2-yl-methoxy)-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl)-3-(1-methylpyrrolidin-2-yl) propenamide dimaleate (called SHR1258 dimaleate for short), preparation methods thereof, and pharmaceutical compositions containing the same. The crystalline Form I of SHR1258 dimaleate has good crystal stability and chemical stability, and can be used in the preparation of medicaments for treating diseases related to EGFR receptor tyrosine kinase or HER-2 receptor tyrosine kinase.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.